Post-earnings recap
Reported
Wed, Aug 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
The earnings report shows that Protagonist Therapeutics continues to invest heavily in its clinical programs, as reflected in their negative EPS. Despite the miss on EPS, the stock rose by 2.17%, likely due to investor optimism about the company's future potential and ongoing projects. The lack of revenue data and guidance suggests uncertainty, but the positive stock reaction indicates confidence among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.18 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains focused on their research and development efforts. They conveyed a sense of optimism about future projects despite not providing specific guidance.
Management highlighted ongoing developments in their pipeline.
They expressed commitment to advancing their clinical programs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—